AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 62 min read$OSTX

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies (NYSE American: OSTX) reported a 72.7% 3-year overall survival rate for OST-HER2-treated patients in its Phase 2b trial, compared to 45.8% in historical controls. The company plans to submit regulatory applications for early market access in the U.S., U.K., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

Original reporting
finance.yahoo.com
Published Oct 6, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$OSTXBullishMed
01

Why it matters

The survival data may accelerate regulatory submissions and attract partnership interest.

02

Market read

First‑report Phase 2b survival data for a biotech; potential catalyst for stock movement.

03

What to watch

Regulatory timelines and potential competition from other HER2 immunotherapies could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

OS Therapies is a clinical‑stage oncology company developing Listeria‑based gene‑edited immunotherapies.

Company-level read

Ticker impact

$OSTXBullishHigh confidence
Context

OS Therapies reported statistically significant 3-year overall survival data from its Phase 2b OST-HER2 trial in pulmonary metastatic osteosarcoma.

Expected impact

likely upward pressure as the market prices in the survival benefit and upcoming regulatory filings.

Evidence & confidence

Phase 2b data with a clear survival advantage is material for a clinical‑stage biotech and may accelerate BLA submission plans.

Market effects

Sector

Strengthens the Listeria‑based immunotherapy niche and may lift peer biotech valuations.

Regional

US and European biotech investors could see increased interest.

Global

Adds to the pipeline momentum for HER2‑targeted therapies worldwide.

Counterpoint

What could challenge this read

Trial size is small (41 patients) and results need confirmation in Phase 3; risk of over‑optimism.

Key entities

  • company
    OS Therapies, Inc.

    Developer of OST-HER2 immunotherapy.

  • executive
    Dr. Craig Eagle

    Chief Medical Advisor commenting on trial results.

Read at source← All news

StoryOS Therapies reports three-year survival benefit in osteosarcoma study

Related articles

OCT 1
$OSTXLow

OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies (NYSE American: OSTX) appointed Kerry Clem as CCO and Frank Knuettel II as CFO. Clem will lead commercialization of Herlystic, their lead immunotherapy for osteosarcoma, with U.S. launch planned post-FDA approval. Knuettel brings financial expertise. The company anticipates regulatory filings in Q4 2026 and has received tax credits for R&D.

finanznachrichten.de2 min
SEP 24
$OSTXMedAI 8/10

OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.

finanznachrichten.de2 min
SEP 21
$OSTXMedAI 8/10

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies (OSTX) updated its global regulatory coordination for OST-HER2 under Project Orbis. The U.K.'s MHRA will lead the process, with a Phase 3 trial set to begin in mid-2026. The FDA aligned on the study design, and the company aims to submit a CMAA soon. OST-HER2 has received multiple designations from the FDA, EMA, and MHRA.

intelligencer.ca2 min
SEP 17
$OSTXMedAI 8/10

OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

OS Therapies (OSTX) aligned with the FDA on its Phase 3 trial design for OST-HER2, a treatment for metastatic osteosarcoma. The company will join Project Orbis, a global regulatory initiative, and aims to submit a BLA in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, and a successful BLA could make the company eligible for a Priority Review Voucher.

finanznachrichten.de2 min
SEP 15
$OSTXHighAI 8/10

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

intelligencer.ca2 min